Engineered t cells with a kill switch aim to make stem cell transplants safer
NCT ID NCT00710892
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causing graft-versus-host disease (GvHD). The goal is to see if higher doses of these modified T cells can help the immune system recover faster while keeping GvHD under control. The trial involves 10 patients with blood cancers or related disorders.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allodepleted T cells with inducible caspase 9 suicide gene
- What this could lead to
- If it works, this could allow safer use of partially matched donor stem cells by giving doctors a way to turn off immune cells that attack the patient's body.
- What could go wrong
- This is a very early phase 1 trial with only 10 participants. The suicide switch has not been proven to work in humans, and patients who develop graft-versus-host disease will still need standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
The Methodist Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?